您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > RS-1
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
RS-1
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
RS-1图片
CAS NO:312756-74-4
规格:≥98%
包装与价格:
包装价格(元)
5mg电议
10mg电议
25mg电议
50mg电议
100mg电议
250mg电议
500mg电议

产品介绍
理化性质和储存条件
Molecular Weight (MW) 524.23
Formula C20H16Br2N2O3S
CAS No. 312756-74-4
Storage-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)DMSO: 100 mg/mL (190.75 mM)
Water: <1 mg/mL
Ethanol: <1 mg/mL
SMILES O=C(NC1=CC=C(Br)C=C1)C2=CC=C(Br)C(S(=O)(NCC3=CC=CC=C3)=O)=C2
Synonyms RAD51-Stimulatory Compound-1; RS-1; RS 1; RS1.
实验参考方法
In Vitro

In vitro activity: RS-1 (formerly known as RAD51-Stimulatory Compound-1) is a small molecule RAD51 activator that enhances hRAD51 binding in a wide range of biochemical conditions. It can also increases CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9)-mediated knock-in efficiencies and has potential anticancer activities. Salt titration experiments showed that RS-1 can enhance filament stability. Ultrastructural analysis of filaments formed on ssDNA showed that RS-1 can increase both protein-DNA complex lengths and the pitch of helical filament turns. RS-1 stimulated hRAD51-mediated homologous strand assimilation (D-loop) activity by at least 5- to 11-fold, depending on the condition. This D-loop stimulation occurred even in the presence of Ca(2+) or adenylyl-imidodiphosphate, indicating that the mechanism of stimulation was distinct from that conferred by Ca(2+) and/or inhibition of ATPase. No D-loop activity was observed in the absence of a nucleotide triphosphate cofactor, indicating that the compound does not substitute for this requirement. These results indicate that RS-1 enhances the homologous recombination activity of hRAD51 by promoting the formation of active presynaptic filaments. Cell survival assays in normal neonatal human dermal fibroblasts demonstrated that RS-1 promotes a dose-dependent resistance to the cross-linking chemotherapeutic drug cisplatin. Given that RAD51-dependent recombination is a major determinant of cisplatin resistance, RS-1 seems to function in vivo to stimulate homologous recombination repair proficiency. RS-1 has many potential applications in both research and medical settings.


Kinase Assay: Briefly, 15 μL reaction volumes include a DNA strand exchange protein (0.8 μM) that is preincubated for 5 min at 37°C with 1 μM (nucleotide concentration) 32P-labeled oligonucleotide 306.7 in a reaction buffer containing 20 mM Hepes (pH 7.5), 1 mM DTT, 2 mM nucleotide cofactor, and 1 mM MgCl2 and various concentrations of RS-1. For experimental buffer conditions that included calcium, 1 mM CaCl2 is present in addition to (in the case of hRAD51) or in the place of (in the case of RecA and scRAD51) the 1 mM MgCl2. Conditions with scRAD51 additionally contains 110 nM scRAD54. After this initial binding reaction, 10 μL of 19.75 μM (base pair concentration) supercoiled homologuecontaining target plasmid DNA (pRS306) is next added along with sufficient magnesium acetate to give a final concentration of 10 mM.


Cell Assay: RS-1 stimulates the binding of hRAD51 to ssDNA. Low-micromolar concentrations of this small molecule enhance DNA binding and result in longer protein–DNA complex lengths. In addition, RS-1 stabilizes the active form of hRAD51 filaments and this is reflected in an enhanced strand assimilation activity

In VivoZinc-finger nuclease, transcription activator-like effector nuclease and CRISPR (clustered regularly interspaced short palindromic repeats)/Cas9 (CRISPR-associated protein 9) are becoming major tools for genome editing. Importantly, knock-in in several non-rodent species has been finally achieved thanks to these customizable nucleases; yet the rates remain to be further improved. We hypothesize that inhibiting non-homologous end joining (NHEJ) or enhancing homology-directed repair (HDR) will improve the nuclease-mediated knock-in efficiency. Here we show that the in vitro application of an HDR enhancer, RS-1, increases the knock-in efficiency by two- to five-fold at different loci, whereas NHEJ inhibitor SCR7 has minimal effects. We then apply RS-1 for animal production and have achieved multifold improvement on the knock-in rates as well. Our work presents tools to nuclease-mediated knock-in animal production, and sheds light on improving gene-targeting efficiencies on pluripotent stem cells.
Animal model
Formulation & Dosage
References Proc Natl Acad Sci U S A. 2008 Oct 14;105(41):15848-53; Nat Commun. 2016 Jan 28;7:10548.